ArticleScientific reports2025
Si-Miao-Yong-An decoction suppresses necroptosis by regulating the p53 pathway in myocardial ischemia/reperfusion injury.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Single Genes to Systemic Networks: Transcriptomic Insights into Traditional Chinese Medicine for Heart Failure.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Myocardial ischemia/reperfusion (I/R) injury is a serious complication during the recanalization treatment of myocardial infarction (MI), which seriously affects the prognosis of patients. As a renowned traditional Chinese medicinal formulation, Si-Miao-Yong-An decoction (SMYA) has therapeutic effects on myocardial I/R injury, although its underlying mechanisms, particularly concerning regulated cell death pathways, are not fully understood. This study aimed to explore the therapeutic effect and possible mechanism of SMYA in myocardial I/R injury. C57BL/6J mice were divided into sham, model, and SMYA-treated groups (low, medium and high-dose). In this study, we identified 13 main components of SMYA using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS). Moreover, SMYA improved cardiac dysfunction caused by myocardial I/R injury, decreased the levels of myocardial injury markers, reduced the myocardial infarct size, and alleviated pathological changes in the myocardium. In addition, transcriptomic analysis predicted that the p53 signaling pathway may be a potential target for its function. To this end, the result of western blotting revealed that SMYA inhibited myocardial cell necroptosis by regulating the p53 and RIPK1/RIPK3/MLKL pathways. Overall, SMYA suppressed necroptotic processes induced by myocardial I/R injury, likely mediated by the modulation of the p53 and RIPK1/RIPK3/MLKL pathways. Therefore, SMYA may be a potential therapeutic agent for treating myocardial I/R injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.